AI Portfolio Risk Modeling for Clinical Trial Decision Support
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pharmaceutical industry faces significant challenges in managing clinical trial risks and optimizing portfolio management due to high attrition rates, complex regulatory environments, and inefficient decision-making processes, leading to a productivity crisis and unsustainable business models.
Innovation Solution
A system and method utilizing artificial intelligence and machine learning to analyze heterogeneous data sources for predictive and prescriptive insights on clinical trial success, including recruitment, protocol deviations, and regulatory and commercial risks, enabling real-time risk monitoring and optimization of pharmaceutical portfolio management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional portfolio management methods are used in pharmaceutical industry, then decision-making processes are simple and transparent, but attrition rates remain high and productivity is low
Solution Approach 1:
The patent replaces traditional mechanical/portfolio management methods with an artificial intelligence-based decision support system. The AI system processes heterogeneous data sources including clinical trial data, regulatory information, and commercial data to generate predictive insights, substituting human judgment and simple analytical methods with machine learning algorithms that can handle complex multidimensional risk assessment.
Solution Approach 2:
The decision support system integrates multiple data sources and analytical methods into a composite approach. It combines structured clinical trial data with unstructured regulatory documents, incorporates multiple machine learning models, and synthesizes diverse risk factors (clinical, regulatory, commercial) into unified predictive metrics for portfolio management decisions.
2Measurement precision
If more data sources are integrated into the analysis system, then prediction accuracy improves, but system complexity and data processing requirements increase
Solution Approach 1:
The system segments the complex data processing task into distinct modules: data acquisition from multiple sources, data preprocessing and cleaning, feature extraction from heterogeneous data types, model training, and prediction generation. This modular architecture allows each component to handle specific data types and processing requirements independently, managing overall system complexity.
Solution Approach 2:
The patent introduces intermediary components including data preprocessing layers that standardize heterogeneous data formats, feature extraction modules that transform raw data into meaningful variables, and model interpretation layers that translate AI predictions into actionable insights. These intermediaries bridge the gap between complex raw data and simplified decision support outputs.
3Reliability
If AI-based predictive analytics are implemented, then risk monitoring capability improves, but implementation costs and computational resources increase
Solution Approach 1:
The system implements partial monitoring by focusing computational resources on the most critical risk factors and high-value portfolio assets. It prioritizes analysis of data from ongoing clinical trials and assets nearing key decision points, rather than continuously processing all portfolio data at maximum depth, thereby reducing overall computational burden while maintaining reliable risk monitoring where it matters most.
Data Source
AI summary
This invention is a method, system, and platform for risk management and decision support in pharmaceuticals, including strategic portfolio management, regulatory affairs, clinical drug development, pharmacoeconomic, investment strategy optimization, risk management, due diligence for mergers and acquisitions, and the stock market. The system uses artificial intelligence and diverse data from open and private sources, including clinical trials, regulatory decisions, economic data, pharmacological data, and corporate data. It integrates multiple decision-making modules for clinical development, such as clinical risk, regulatory risk, pharmacological risk, and economic risk. This network of risk factors generates predictive and prescriptive information for strategic decision-making.